Liposome Drug Delivery Market Report 2025 by Delvens offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance, the global Liposome Drug Delivery Market size is projected to reach a CAGR of 9.8% and Forecast to 2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/liposome-drug-delivery-market
Liposome drug delivery is a way of administering a medication that increases its bioavailability and reduces toxicity. Liposomes are tiny vesicles made from naturally occurring molecules in the body, which can transport drugs into targeted cells for improved effectiveness while reducing side effects compared to conventional methods like intravenous injections or oral medications.
The growth of the market can be attributed to the rising prevalence of cancer, and therefore the need for advanced drug delivery systems for the treatment of the disease. the rising focus of healthcare researchers on developing targeted drug delivery systems (TDDS) is also expected to create numerous opportunities for market growth.
Recent Developments
Ipsen Pharma announced that it has received the Fast Track designation by the United States Food and Drug Administration (FDA) for the investigational use of liposomal irinotecan (ONIVYDE) in combination with oxaliplatin (OX) and 5-fluorouracil/leucovorin (5-FU/LV) together.
FUJIFILM Toyama Chemical Co., Ltd. announced that it has completed its first manufacturing facility named 701 for liposome formulation in Japan.
The Prominent Players in Liposome Drug Delivery Market are:
- Johnson and Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
- Spectrum Pharmaceuticals
- Shanghai New Asia and More
Liposome Drug Delivery Market is segmented into various segments such as product, technology, application and region:
On the basis of product
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphotericin B
- Others
On the basis of technology
- Stealth Liposome Technology
- Non-PEGylated Liposome Technology
- DepoFoam Liposome Technology
- Lysolipid Thermally Sensitive Liposome (LTSL) Technology
On the basis of application
- Fungal Diseases
- Cancer Therapy
- Pain Management
- Viral Vaccines
- Photodynamic Therapy
On the basis of region
- Asia Pacific
- North America
- Europe
- South America
- Middle East & Africa
Access Full Report: https://www.delvens.com/report/liposome-drug-delivery-market
Access More Reports:
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
Unit No. 01, 3rd Floor, Plot No. 56, Block B
Sector 2 Noida, Near Noida Sector 15 Metro Station 201301, IN
+44 20 3290 6466
+0120- 4903958
